Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AZD0780

Small molecule · developed by ASTRAZENECA

Phase 2/3 Most advanced trial
AZN Developer
1 Registered trials

What is AZD0780?

AZD0780 is an oral tablet formulation studied in dyslipidaemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Cardiovascular
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
9EEL3YMY29

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06834932 Phase 2/3 Dyslipidaemia Active not recruiting AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dyslipidaemia

More from ASTRAZENECA

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind AZD0780

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.